Skip to main content

Table 4 Comparison of platinum group vs. non – platinum group

From: Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

Characteristics Platinum Group (%) Non-Platinum Group (%) P value
Total Number 177 66  
Median age, years (range) 58 (range 26–81) 64 (range 29–80) 0.003
Sex    0.247
   Male 112 (63.3) 47 (71.2)  
   Female 65 (36.7) 19 (28.8)  
ECOG performance status at baseline    0.047
   0 – 1 161 (91.0) 54 (81.8)  
   ≥ 2 16 (9.0) 12 (18.2)  
Disease    0.361
   Intrahepatic cholangiocarcinoma 72 (40.7) 20 (30.3)  
   Gallbladder cancer 51 (28.8) 20 (30.3)  
   Extrahepatic bile duct cancer 38 (21.5) 22 (22.2)  
   Ampulla of Vater carcinoma 16 (9.0) 5 (7.6)  
Relapsed disease 62 (35.0) 22 (33.3) 0.805
Biliary stent or bypass during treatment 46 (26.0) 18 (27.3) 0.84
Disease associated infection during treatment (cholangitis, liver abscess) 43 (24.3) 19 (28.8) 0.475
Duration from off chemotherapy to death 3.3 months (95% CI, 2.6–3.9) 4.0 months (95% CI, 2.6–5.5) 0.071
  1. ECOG, Eastern Cooperative Oncology Group; CI, confidence interval